Syncom Formulations (India) Cash Flow
- Market cap
- ₹2,183 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹16.72 – ₹31.35
In the year ended FY25, Syncom Formulations (India) generated ₹131 crore from operating activities, invested ₹87.31 crore and paid out ₹32.74 crore on financing activities. Net cash flow for the year was ₹10.91 crore. Free cash flow was ₹54.57 crore.
Syncom Formulations (India) cash flow statement
Financial years, newest first. Negative figures are cash outflows.
| Item | FY25 |
|---|---|
| Cash from operating activities | 131 |
| Cash from investing activities | -87.31 |
| Cash from financing activities | -32.74 |
| Net cash flow | 10.91 |
| Capital expenditure | 76.39 |
| Free cash flow | 54.57 |
Source: Company filings, in ₹ crore. Data as of 9 October 2026. How this data is compiled.
Syncom Formulations (India) cash flow — frequently asked questions
What is Syncom Formulations (India)'s operating cash flow?
Syncom Formulations (India)'s cash flow from operating activities was ₹131 crore in the year ended FY25.
What is Syncom Formulations (India)'s free cash flow?
Syncom Formulations (India)'s free cash flow — operating cash flow minus capital expenditure — was ₹54.57 crore in FY25, after capital expenditure of ₹76.39 crore.
How much did Syncom Formulations (India) spend on investing activities?
Net cash used in investing activities was ₹87.31 crore in FY25. This covers capital expenditure, acquisitions and the purchase or sale of investments.
Same Data For Peers
Trade Syncom Formulations (India) With ATS
Track SYNCOMF live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.